blinkx

  • New CDC Safety Analyses Support Safety Profile Of Cervical Cancer Vaccine

  • 00:05:51
  • NewsInfusion
    • Browse

New CDC Safety Analyses Support Safety Profile Of Cervical Cancer Vaccine

October 22, 2008 - Preliminary results from a large safety study, called the Vaccine Safety Datalink (VSD) project, presented for the first time today by the Centers for Disease Control and Prevention (CDC) at the Advisory Committee on Immunization Practices (ACIP) meeting did not find statistically significant risk for any of the pre-specified adverse events following vaccination with GARDASILÒ [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] compared to those who were not vaccinated. This finding was based on more than 375,000 doses of GARDASIL administered. More about Cervial Cancer Vaccine Safety

NewsInfusion | May 4, 2009Watch more videos from NewsInfusion

Tags:. .did. .presented. .today. .those. .based











Administered   Adverse   Advisory   Analyses   Based   Cancer   Cdc   Centers   Cervical   Committee   Compared   Control   Did   Disease   Doses   Events   Following   Human   Immunization   Large   Meeting   October   Practices   Preliminary   Presented   Prevention   Profile   Project   Results   Risk   Safety   Significant   Statistically   Study   Support   Those   Today   Types   Vaccinated   Vaccination   Vaccine